This inventor holds 1 USPTO granted patent. Top assignees: Centre National De La Recherche Scientifique, Institut Pasteur De Lille, National Institute of Health and Medical Research. Active years: 2026.
Company Filing History:
1 out of 5,383 
1 out of 65 
1 out of 1,853 
Years Active: 2026
Title: Innovations in Tuberculosis Treatment by Alain Boulard
Introduction
Alain Boulard is a notable inventor based in Lille, France. He has made significant contributions to the field of medical research, particularly in the treatment of tuberculosis. His innovative approach focuses on the use of materials made of cross-linked β-cyclodextrins, which have shown promise in addressing multi-drug resistant tuberculosis.
Latest Patents
Alain Boulard holds 1 patent for his work titled "Use of materials made of cross-linked β-cyclodextrins for the treatment of tuberculosis." This patent addresses a critical public health issue, as multi-drug resistant tuberculosis affects approximately half a million individuals each year. The current treatment regimen is cumbersome, requiring patients to adhere to a strict regimen of over 10,000 tablets over a two-year period. Boulard's research highlights the need for more efficient and better-formulated medications.
Career Highlights
Throughout his career, Alain Boulard has demonstrated a commitment to advancing medical science. His research has shown that nanoparticles made of cross-linked poly-β-cyclodextrins (pβCD) serve as effective vehicles for the pulmonary delivery of powerful combinations of anti-TB drugs. Furthermore, these nanoparticles possess intrinsic antibacterial properties, which enhance their effectiveness in treating tuberculosis.
Collaborations
Alain Boulard has collaborated with esteemed colleagues such as Arnaud Machelart and Ruxandra Gref. He has also worked with reputable institutions, including the National Institute of Health and Medical Research and the Centre National De La Recherche Scientifique.
Conclusion
Alain Boulard's innovative work in the treatment of tuberculosis through the use of cross-linked β-cyclodextrins represents a significant advancement in medical research. His contributions have the potential to improve patient outcomes and address a pressing global health challenge.